CRIS Current Research Information System

CECI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.592
AS - Asia 5.577
EU - Europa 3.622
AF - Africa 355
SA - Sud America 301
OC - Oceania 8
AN - Antartide 1
Totale 15.456
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.528
VN - Vietnam 1.733
SG - Singapore 1.447
CN - Cina 1.235
GB - Regno Unito 920
IT - Italia 632
DE - Germania 466
HK - Hong Kong 424
SE - Svezia 421
FR - Francia 267
IN - India 248
RU - Federazione Russa 228
BR - Brasile 211
IE - Irlanda 145
ZA - Sudafrica 113
NL - Olanda 98
FI - Finlandia 96
KR - Corea 95
TG - Togo 86
JP - Giappone 79
EE - Estonia 74
CI - Costa d'Avorio 70
JO - Giordania 65
CH - Svizzera 53
UA - Ucraina 48
AR - Argentina 43
CA - Canada 43
BG - Bulgaria 40
BD - Bangladesh 36
BE - Belgio 29
SC - Seychelles 29
IR - Iran 27
TH - Thailandia 27
ID - Indonesia 26
NG - Nigeria 22
PL - Polonia 22
AT - Austria 20
ES - Italia 20
PH - Filippine 20
EC - Ecuador 19
IQ - Iraq 16
TR - Turchia 16
MX - Messico 15
TW - Taiwan 15
SA - Arabia Saudita 11
CL - Cile 10
PK - Pakistan 10
UZ - Uzbekistan 9
LT - Lituania 8
MY - Malesia 8
RO - Romania 8
AU - Australia 7
CO - Colombia 6
EG - Egitto 6
ET - Etiopia 6
VE - Venezuela 6
AL - Albania 5
KZ - Kazakistan 5
MA - Marocco 5
CZ - Repubblica Ceca 4
GR - Grecia 4
LB - Libano 4
TN - Tunisia 4
HR - Croazia 3
NP - Nepal 3
OM - Oman 3
PT - Portogallo 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
AZ - Azerbaigian 2
BO - Bolivia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GA - Gabon 2
KE - Kenya 2
KG - Kirghizistan 2
PS - Palestinian Territory 2
SV - El Salvador 2
UY - Uruguay 2
AM - Armenia 1
AQ - Antartide 1
BY - Bielorussia 1
CG - Congo 1
CM - Camerun 1
CR - Costa Rica 1
CY - Cipro 1
GE - Georgia 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PE - Perù 1
PY - Paraguay 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 15.453
Salva come PNG Salva come JPEG
Città #
Singapore 1.007
Southend 826
Ashburn 641
Fairfield 605
Chandler 405
Hong Kong 404
San Jose 281
Ho Chi Minh City 277
Seattle 272
Santa Clara 271
Houston 266
Wilmington 266
Woodbridge 258
Hanoi 238
Cambridge 229
Princeton 184
Hefei 160
Beijing 159
Dublin 145
Ann Arbor 133
Bologna 130
Dong Ket 124
Lauterbourg 113
Boardman 106
Westminster 89
Lomé 86
Los Angeles 86
Helsinki 83
Nanjing 73
Seoul 73
Berlin 71
Abidjan 70
Padova 68
Amman 64
Tokyo 58
New York 54
Redondo Beach 50
Milan 49
Da Nang 46
Bern 45
Jinan 42
Shenyang 40
Dallas 39
Haiphong 39
Munich 39
Sofia 36
Buffalo 34
Florence 34
Saint Petersburg 33
Guangzhou 31
San Diego 31
Turin 31
Changsha 30
Frankfurt am Main 29
Medford 29
Brussels 27
Hebei 27
Nanchang 27
Johannesburg 26
Bremen 25
Redwood City 23
Rome 23
São Paulo 23
Toronto 23
Tianjin 22
Nuremberg 21
Abeokuta 20
Zhengzhou 20
London 18
Bengaluru 17
Orem 17
Council Bluffs 16
Phoenix 16
Biên Hòa 15
Norwalk 15
Amsterdam 14
Brooklyn 14
Dearborn 14
Jiaxing 14
Yubileyny 14
Chicago 13
Falkenstein 13
Shanghai 13
Warsaw 13
Falls Church 12
Mumbai 12
Taiyuan 12
Thái Bình 12
Vienna 12
Shenzhen 11
Taizhou 11
Atlanta 10
Baghdad 10
Des Moines 10
Hangzhou 10
Jakarta 10
Quận Bình Thạnh 10
Wuhan 10
Bangkok 9
Chengdu 9
Totale 9.795
Salva come PNG Salva come JPEG
Nome #
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? 337
The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence 269
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 231
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. 222
11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard 220
Prediction Nomogram for 68 Ga-PSMA-11 PET/CT in Different Clinical Settings of PSA Failure After Radical Treatment for Prostate Cancer 218
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 215
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 210
11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. 208
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 207
11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. 207
68Ga-PSMA PET/CT for restaging prostate cancer after definitive therapy: Results of a prospective single-center trial 201
11C-Choline PET/CT for Restaging of Bladder Cancer 200
How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? 197
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and midterm follow-up 193
18f-fdg pet/ct for restaging gastric cancer after surgical resection 190
68Ga-PSMA PET/CT in prostate cancer 190
11C-Choline PET/CT in hormonal resistant patients after radical prostatectomy 188
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 187
11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. 186
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 184
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 182
Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer patient 181
18F-FACBC PET/CT in comparison to 11c-choline for the detection of prostate cancer relapse after radical prostatectomy: A perspective study in 50 patients 180
(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer 175
PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment 170
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 169
Erratum to: Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. 167
11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. 163
18F-FACBC PET/CT VS. 11C-CHOLINE FOR THE DETECTION OF PROSTATE CANCER RELAPSE AFTER RADICAL TREATMENT 162
Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. 161
Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT. 160
DIAGNOSTIC ACCURACY OF 11C-CHOLINE PET/CT IN COMPARISON WITH CONTRASTENHANCED CT IN THE PREOPERATIVE LYMPH-NODE STAGING OF BLADDER CANCER USING THE PATHOLOGICAL SPECIMENS AS REFERENCE STANDARD 160
The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. 159
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. 159
Current Application and Future Perspectives of Prostate Specific Membrane Antigen PET Imaging in Prostate Cancer 159
Response Evaluation to Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer using 11C-choline PET/CT and Bone Scintigraphy 156
DIAGNOSTIC ACCURACY OF 11C-CHOLINE PET/CT COMPARED TO CONTRASTENHANCED CT IN THE POSTOPERATIVE RESTAGING OF RECURRENT BLADDER CANCER: ANALYSIS OF 20 CONSECUTIVE PATIENTS 154
Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial 151
State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer 151
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. 151
New radiopharmaceutical markers for metabolism and receptor 150
First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. 149
State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. 149
Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database 149
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 148
Asymptomatic and symptomatic deep venous thrombosis in hospitalized acutely ill medical patients: risk factors and therapeutic implications 147
68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: Impact on salvage radiotherapy planning 147
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. 146
A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. 146
PET/CT and prostate cancer 146
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? 145
11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series 144
Role of 11C-Choline PET/CT in androgen sensitive prostate cancer patients treated with intermittent ADT: A sequential PET/CT study after therapy interruption 143
IL RUOLO DELLA 11C-COLINA PET/CT IN PAZIENTI CON RECIDIVA BIOCHIMICA DOPO PROSTATECTOMIA RADICALE E CARCINOMA PROSTATICO ORMONO-RESISTENTE SOTTOPOSTI A TERAPIA DI DEPRIVAZIONE ANDROGENICA 143
PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. 141
Yttrium 90 Intra Arterial Radioembolization Therapy of Unresectable Intrahepatic Cholangiocarcinoma: 5 Year Experience at a Single Center 140
Ga-68-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels< 2 ng/mL 138
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis 137
Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: preliminary results 137
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial 137
PREOPERATIVE 11C-CHOLINE PET-CT IN INTERMEDIATE, HIGH RISK AND VERY HIGH RISK PROSTATE CANCER PATIENTS: IS THERE STILL ANY ROOM LEFT FOR IT? 135
Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. 133
68Ga-Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer: A Case Report 132
Clinical impact of 11C-Choline PET/CT in recurrent prostate cancer patients after radical therapy: Which is the real impact on treatment decisions? 129
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml 128
PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications 128
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68 Ga-PSMA-11 PET/CT 128
Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. 127
Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view. 125
Role of 18F-FDG PET/CT in the restaging of patients affected by clear cell renal carcinoma 125
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer 124
Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. 124
PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. 123
68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. 123
New aspects of molecular imaging in prostate cancer. 122
Molecular Imaging and Precision Medicine in Prostate Cancer 121
PET/CT in prostate cancer 121
Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer: A Systematic Comparison With Contrast-Enhanced CT and Histologic Findings. 121
null 119
Comparison of68Ga-PSMA-11 PET/CT and18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence 118
Detection of sarcomatoid lung metastasis with 68GA-PSMA PET/CT in a patient with prostate cancer 116
The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals 116
A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study 115
null 113
Reply: Comparison of68Ga-PSMA-11 and18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective trial is on its way 111
Therapy assessment in prostate cancer using choline and PSMA PET/CT. 109
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy 107
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. 106
The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? 106
A new type of prostate cancer imaging. Will64CuCl2PET/CT flourish or vanish? 105
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. 105
Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence 100
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. 99
Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders 99
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: Nodal oligorecurrent prostate cancer 89
SEM, TEM, and IHC Analysis of the Sinus Node and Its Implications for the Cardiac Conduction System 88
What is the best PET target for early biochemical recurrence of prostate cancer?–Authors’ reply 88
New radiopharmaceutical Markers for Matebolism and receptor 85
Potential impact of 68Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer 84
Totale 15.059
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.391
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.391
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021449 0 0 0 0 0 0 0 0 0 43 35 371
2021/20221.983 554 58 97 126 170 78 49 114 62 59 357 259
2022/20231.949 172 288 112 254 115 133 50 103 386 89 145 102
2023/2024555 75 85 26 54 39 90 30 34 22 42 29 29
2024/20252.341 114 344 173 187 430 151 131 49 24 122 108 508
2025/20264.799 482 398 418 361 577 269 503 232 1.137 422 0 0
Totale 15.761